Vir Biotechnology Announced That Its 2020 Research Collaboration Agreement With Gsk Is Amended To Reflect That Vir Will Continue Its Ongoing Efforts To Discover, Develop And Advance Next-Generation Solutions For Covid-19 And Other Potential Coronavirus Epidemics, Independently Or With Other Partners.The Companies Will Continue To Work Together To Ensure Continued Availability Of Sotovirumab To Patients Around The World, Post-Licencing, And To Develop New Therapies For Influenza And Other Respiratory Diseases.Under The Terms Of The New Amended Agreement, Vir Retains The Sole Rights To Continue Advancing Next-Generation Solutions Arising From The Collaborative Coronavirus Vaccine And Antibody Programmes, Subject To Tiered Low- To Mid-Single Digit Royalties To Gsk. The Companies Continue To Collaborate On Sotrovimab And Vir-7832, As Well As A Portfolio Of Other Respiratory Disease Programmes.In April 2020, Gsk And Vir Entered Into A Collaboration To Research And Develop Solutions For Coronaviruses, Including Sars-Cov-2, The Virus That Causes Covid-19. The Collaboration Used Vir
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!